Purpose: The COMBINE Trial will study if treatment with a single anti-TNF medication (infliximab and adalimumab) or dual therapy that includes methotrexate is more effective in children with moderate to severe Crohn’s disease. COMBINE is the first study to look at this question in children with Crohn’s disease. We expect that 425 kids from across the US will enter the study. The results of this study can be used to help doctors choose medications that help children the most.
Funding Source (Year Awarded): Patient Centered Outcomes Research Institute (2015)
Study Period: 2015-2020
Recruitment Status: Complete - Manuscript published April 2023 in Gastroenterology
For more information
Researchers Announce Findings from Landmark Clinical Trial for Pediatric Crohn's Disease - UNC Health
ICN Posts